Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • JASN Podcasts
    • Article Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Editorial Fellowship
    • Editorial Fellowship Team
    • Editorial Fellowship Application Process
  • More
    • About JASN
    • Advertising
    • Alerts
    • Feedback
    • Impact Factor
    • Reprints
    • Subscriptions
  • ASN Kidney News
  • Other
    • ASN Publications
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • ASN Publications
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • JASN Podcasts
    • Article Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Editorial Fellowship
    • Editorial Fellowship Team
    • Editorial Fellowship Application Process
  • More
    • About JASN
    • Advertising
    • Alerts
    • Feedback
    • Impact Factor
    • Reprints
    • Subscriptions
  • ASN Kidney News
  • Follow JASN on Twitter
  • Visit ASN on Facebook
  • Follow JASN on RSS
  • Community Forum
Clinical Dialysis
You have accessRestricted Access

Activated Injectable Vitamin D and Hemodialysis Survival: A Historical Cohort Study

Ming Teng, Myles Wolf, M. Norma Ofsthun, J. Michael Lazarus, Miguel A. Hernán, Carlos A. Camargo and Ravi Thadhani
JASN April 2005, 16 (4) 1115-1125; DOI: https://doi.org/10.1681/ASN.2004070573
Ming Teng
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Myles Wolf
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Norma Ofsthun
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. Michael Lazarus
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Miguel A. Hernán
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carlos A. Camargo Jr
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ravi Thadhani
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data Supps
  • Info & Metrics
  • View PDF
Loading

Abstract

Patients with ESRD commonly experience secondary hyperparathyroidism, a condition primarily managed with activated injectable vitamin D. The biologic effects of vitamin D, however, are widespread, and it is possible that activated injectable vitamin D alters survival in ESRD. This hypothesis was tested in a historical cohort study of incident hemodialysis patients who lived throughout the United States between January 1996 and December 1999. The primary outcome was 2-yr survival among those who survived for at least 90 d after initiation of chronic hemodialysis. During this period, 51,037 chronic hemodialysis patients survived for at least 90 d from the initiation of hemodialysis, and in the ensuing 2 yr, 37,173 received activated injectable vitamin D and 13,864 did not. At 2 yr, mortality rates were 13.8/100 person-years in the group that received injectable vitamin D compared with 28.6/100 person-years in the group that did not (P < 0.001). Cox proportional hazards analyses adjusting for several potential confounders and examining injectable vitamin D therapy as a time-dependent exposure suggested that compared with patients who did not receive injectable vitamin D, the 2-yr survival advantage associated with the group that did receive injectable vitamin D was 20% (hazard ratio, 0.80; 95% confidence interval, 0.76 to 0.83). The incidence of cardiovascular-related mortality was 7.6/100 person-years in the injectable vitamin D group, compared with 14.6/100 person-years in the non–vitamin D group (P < 0.001). The benefit of injectable vitamin D was evident in 48 of 49 strata examined, including those with low serum levels of intact parathyroid hormone and elevated levels of serum calcium and phosphorus, situations in which injectable vitamin D is often withheld. Repeating the entire analysis using marginal structural models to adjust for time-dependent confounding by indication yielded a survival advantage of 26% (hazard ratio, 0.74; 95% confidence interval, 0.71 to 0.79) associated with the injectable vitamin D group. In this historical cohort study, chronic hemodialysis patients in the group that received injectable vitamin D had a significant survival advantage over patients who did not. Randomized clinical trials would permit definitive conclusions.

  • © 2005 American Society of Nephrology
View Full Text
PreviousNext
Back to top

In this issue

Journal of the American Society of Nephrology: 16 (4)
Journal of the American Society of Nephrology
Vol. 16, Issue 4
1 Apr 2005
  • Table of Contents
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in JASN.
Enter multiple addresses on separate lines or separate them with commas.
Activated Injectable Vitamin D and Hemodialysis Survival: A Historical Cohort Study
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Activated Injectable Vitamin D and Hemodialysis Survival: A Historical Cohort Study
Ming Teng, Myles Wolf, M. Norma Ofsthun, J. Michael Lazarus, Miguel A. Hernán, Carlos A. Camargo, Ravi Thadhani
JASN Apr 2005, 16 (4) 1115-1125; DOI: 10.1681/ASN.2004070573

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Activated Injectable Vitamin D and Hemodialysis Survival: A Historical Cohort Study
Ming Teng, Myles Wolf, M. Norma Ofsthun, J. Michael Lazarus, Miguel A. Hernán, Carlos A. Camargo, Ravi Thadhani
JASN Apr 2005, 16 (4) 1115-1125; DOI: 10.1681/ASN.2004070573
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgment
    • Footnotes
    • References
  • Figures & Data Supps
  • Info & Metrics
  • View PDF

More in this TOC Section

  • Comparison of Survival of Upper Arm Arteriovenous Fistulas and Grafts after Failed Forearm Fistula
  • Progressive Exercise for Anabolism in Kidney Disease (PEAK): A Randomized, Controlled Trial of Resistance Training during Hemodialysis
  • Soluble CD154 Is a Unique Predictor of Nonfatal and Fatal Atherothrombotic Events in Patients Who Have End-Stage Renal Disease and Are on Hemodialysis
Show more Clinical Dialysis

Cited By...

  • Calcitriol Accelerates Vascular Calcification Irrespective of Vitamin K Status in a Rat Model of Chronic Kidney Disease with Hyperphosphatemia and Secondary Hyperparathyroidism
  • Vitamin D deficiency in relation to the poor functional outcomes in nondiabetic patients with ischemic stroke
  • Cholecalciferol, Calcitriol, and Vascular Function in CKD: A Randomized, Double-Blind Trial
  • Epidemiology and Mechanisms of Uremia-Related Cardiovascular Disease
  • Is Nutritional Vitamin D Supplementation Beneficial in Dialysis Patients?
  • Risk of Heart Failure Among Postmenopausal Women: A Secondary Analysis of the Randomized Trial of Vitamin D Plus Calcium of the Women's Health Initiative
  • Associations of FGF-23 and sKlotho with Cardiovascular Outcomes among Patients with CKD Stages 2-4
  • Confounded Complexity: Vitamin D, Parathyroid Hormone, and Metabolic Syndrome in Peritoneal Dialysis
  • Angiotensin-Converting Enzyme Inhibitor, Angiotensin Receptor Blocker Use, and Mortality in Patients With Chronic Kidney Disease
  • Effect of Paricalcitol on Left Ventricular Mass and Function in CKD--The OPERA Trial
  • A Plasma Long-Chain Acylcarnitine Predicts Cardiovascular Mortality in Incident Dialysis Patients
  • Effects of Cholecalciferol on Functional, Biochemical, Vascular, and Quality of Life Outcomes in Hemodialysis Patients
  • Effects of Phosphate Binders in Moderate CKD
  • Vascular Klotho Deficiency Potentiates the Development of Human Artery Calcification and Mediates Resistance to Fibroblast Growth Factor 23
  • Racial Differences in Markers of Mineral Metabolism in Advanced Chronic Kidney Disease
  • Vitamin D Therapy in Chronic Kidney Disease and End Stage Renal Disease
  • Vitamin D Status and Mortality of German Hemodialysis Patients
  • Access Survival amongst Hemodialysis Patients Referred for Preventive Angiography and Percutaneous Transluminal Angioplasty
  • Selective Knockout of the Vitamin D Receptor in the Heart Results in Cardiac Hypertrophy: Is the Heart a Drugable Target for Vitamin D Receptor Agonists?
  • Vitamin D and Cardiovascular Disease: Will It Live Up to its Hype?
  • Hemodialysis Treatment Time: A Fresh Perspective
  • Active Vitamin D and Acute Respiratory Infections in Dialysis Patients
  • Elevated Fibroblast Growth Factor 23 is a Risk Factor for Kidney Transplant Loss and Mortality
  • Secondary Hyperparathyroidism: Pathogenesis, Disease Progression, and Therapeutic Options
  • Prescribed Dietary Phosphate Restriction and Survival among Hemodialysis Patients
  • Survival Benefits with Vitamin D Receptor Activation: New Insights Since 2003
  • Forging Forward with 10 Burning Questions on FGF23 in Kidney Disease
  • Fibroblast Growth Factor 23 and Disordered Vitamin D Metabolism in Chronic Kidney Disease: Updating the "Trade-off" Hypothesis
  • Control of Secondary Hyperparathyroidism by Vitamin D Receptor Agonists in Chronic Kidney Disease
  • Clinical Measures Identify Vitamin D Deficiency in Dialysis
  • Vitamin D Receptor Activators Induce an Anticalcific Paracrine Program in Macrophages: Requirement of Osteopontin
  • Effects of Cinacalcet and Concurrent Low-Dose Vitamin D on FGF23 Levels in ESRD
  • Second Chances in Mineral Metabolism
  • Is Calcitriol Life-Protective for Patients with Chronic Kidney Disease?
  • Vitamin D and the Cardiovascular System
  • Clinical Outcomes with Active versus Nutritional Vitamin D Compounds in Chronic Kidney Disease
  • Low Calcidiol Levels and Coronary Artery Calcification: True, True, and Related?
  • 25-Hydroxyvitamin D Levels Inversely Associate with Risk for Developing Coronary Artery Calcification
  • Vascular Calcification: The Killer of Patients with Chronic Kidney Disease
  • Vitamin D Affects Survival Independently of Vascular Calcification in Chronic Kidney Disease
  • Novel therapeutic agents and strategies for the management of chronic kidney disease mineral and bone disorder
  • Plasma Gelsolin and Circulating Actin Correlate with Hemodialysis Mortality
  • Anticoagulant and Antiplatelet Usage Associates with Mortality among Hemodialysis Patients
  • Cinacalcet Lowers Serum Alkaline Phosphatase in Maintenance Hemodialysis Patients
  • Phosphorus Binders and Survival on Hemodialysis
  • Phosphorus and Survival: Key Questions That Need Answers
  • Treatment of Secondary Hyperparathyroidism in CKD Patients with Cinacalcet and/or Vitamin D Derivatives
  • Serum Alkaline Phosphatase Predicts Mortality among Maintenance Hemodialysis Patients
  • Ratio of Paricalcitol Dosage to Serum Parathyroid Hormone Level and Survival in Maintenance Hemodialysis Patients
  • The "Sunshine Deficit" and Cardiovascular Disease
  • Paricalcitol Inhibits Renal Inflammation by Promoting Vitamin D Receptor-Mediated Sequestration of NF-{kappa}B Signaling
  • Consistent Control of Mineral and Bone Disorder in Incident Hemodialysis Patients
  • Nephrology Potpourri
  • Vitamin D and Kidney Disease
  • Active Vitamin D and Survival
  • Association of Oral Calcitriol with Improved Survival in Nondialyzed CKD
  • Vitamin D Receptor Activators Can Protect against Vascular Calcification
  • Impact of Activated Vitamin D and Race on Survival among Hemodialysis Patients
  • Serum 25-hydroxyvitamin D status and cardiovascular outcomes in chronic peritoneal dialysis patients: a 3-y prospective cohort study
  • A Bimodal Association of Vitamin D Levels and Vascular Disease in Children on Dialysis
  • Contribution of Bone and Mineral Abnormalities to Cardiovascular Disease in Patients with Chronic Kidney Disease
  • History-Adjusted Marginal Structural Analysis of the Association between Hemoglobin Variability and Mortality among Chronic Hemodialysis Patients
  • Effects of Sevelamer Hydrochloride and Calcium Carbonate on Renal Osteodystrophy in Hemodialysis Patients
  • Bone and Mineral Guidelines for Patients with Chronic Kidney Disease: A Call for Revision
  • Battleground: Chronic Kidney Disorders Mineral and Bone Disease Calcium Obsession, Vitamin D, and Binder Confusion
  • Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals
  • Role of Hyperphosphatemia and 1,25-Dihydroxyvitamin D in Vascular Calcification and Mortality in Fibroblastic Growth Factor 23 Null Mice
  • Cardiovascular Events and Parathyroid Hormone--Suggestion of a Further Link
  • Metabolic Bone Disease in Chronic Kidney Disease
  • Vitamin D Supplementation and Cardiovascular Disease Risk
  • Mineral Metabolism and Arterial Functions in End-Stage Renal Disease: Potential Role of 25-Hydroxyvitamin D Deficiency
  • An integrated approach to prognosis using protein microarrays and nonparametric methods
  • Vascular Calcifications: Pathogenesis, Management, and Impact on Clinical Outcomes
  • Vitamin D3-Triggered Antimicrobial Response--Another Pleiotropic Effect beyond Mineral and Bone Metabolism: Toll-Like Receptor Triggering of a Vitamin D-Mediated Human Antimicrobial Response. Science 311: 1770-1773, 2006
  • Cohort Studies: Marching Forward
  • Role of Phosphorus and Vitamin D Analogs in the Pathogenesis of Vascular Calcification
  • Associations between Changes in Hemoglobin and Administered Erythropoiesis-Stimulating Agent and Survival in Hemodialysis Patients
  • Cinacalcet Hydrochloride (Sensipar) in Hemodialysis Patients on Active Vitamin D Derivatives with Controlled PTH and Elevated Calcium x Phosphate
  • Time-Dependent Associations between Iron and Mortality in Hemodialysis Patients
  • Fibroblast Growth Factor-23 Mitigates Hyperphosphatemia but Accentuates Calcitriol Deficiency in Chronic Kidney Disease
  • Google Scholar

Similar Articles

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Annual Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Author Resources
  • Editorial Fellowship Program
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • JASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About JASN
  • JASN Email Alerts
  • JASN Key Impact Information
  • JASN Podcasts
  • JASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe to ASN Journals
  • Wolters Kluwer Partnership

© 2022 American Society of Nephrology

Print ISSN - 1046-6673 Online ISSN - 1533-3450

Powered by HighWire